Spots Global Cancer Trial Database for The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.
Official Title: The Safety and Efficacy Study of Autologous Tumor-infiltrating Lymphocyte (TILs) Therapy Combined With Conventional Chemotherapy for Patients With Advanced Stage of Glioblastoma Multiforme.
Study ID: NCT05333588
Conditions
Interventions
Study Description
Brief Summary: The study is to evaluate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy for patients with maligant glioblastoma multiforme. Autologous TiLs should be given by intravenous infusion after 5 days of lymphodepletion treatment.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Second Hospital of HeBei Medical University, Shijiazhuang, Hebei, China
Contact Details
Name: Chunyan Li, academician
Affiliation: Member of the Chinese Academy of Engineering
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
